Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!
oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]
AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.
- AstraZeneca-Dizal deal opens US access to sunvozertinib (3)
- Testing, treatment gaps and rising rare-NSCLC approvals (3)
- WU-KONG1B confirms sunvozertinib activity in EGFR Exon20 (3)
AstraZeneca-Dizal deal opens US access to sunvozertinib
Testing, treatment gaps and rising rare-NSCLC approvals
WU-KONG1B confirms sunvozertinib activity in EGFR Exon20
Stopping myeloma maintenance after two years shows no survival loss in trial
medicalxpress - For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment. A randomized phase 3…
AI Summary: Long‑term follow‑up from a randomized multiple myeloma maintenance study indicates that stopping lenalidomide after two years yields similar overall survival to continuing indefinitely. The data support a limited‑duration maintenance strategy that may spare patients toxicity and costs without sacrificing outcomes — revolutionary for weary patients and budget‑conscious oncologists alike.
- Clinicians and advocates react: praise and guidance after ENDURANCE results (6)
- ENDURANCE trial: Two-year lenalidomide equals continuous therapy (3)
Clinicians and advocates react: praise and guidance after ENDURANCE results
ENDURANCE trial: Two-year lenalidomide equals continuous therapy
Anthropic pushes deeper into healthcare with Optum partnership as UST embeds Claude into claims management
fiercehealthcare - UST, a global technology and engineering services company, is integrating Anthropic's Claude into CarePath, an operational platform for health insurers and providers.
AI Summary: Anthropic struck a deal with Optum to deploy its Claude AI across claims and care-management workflows, marking a significant step in commercial AI integration into health operations. The partnership promises automation and efficiency but raises questions about oversight, accuracy, and accountability when critical administrative decisions quietly migrate to large language models.
Senate Republicans block effort to repeal Medicare AI prior authorization pilot
Jakob Emerson / beckershospitalreview - Senate Republicans have blocked an effort to advance a Democratic-led resolution to repeal CMS’ Wasteful and Inappropriate Service Reduction model, an AI-assisted prior authorization pilot within the traditional Medicare program. On July 16, senators vote…
AI Summary: Senators blocked a bipartisan bid to end a Medicare pilot using AI for prior authorization, effectively keeping the demonstration alive. The vote keeps contentious AI-driven administrative streamlining in place while critics warn about oversight, patient impact and the risks of automating care-denial pathways without robust safeguards.